https://prabadinews.com/
  • October 13, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Efficacy, Safety, and Immunogenicity Maintained When Patients With nAMD Switch from Eylea to Biosimilar

Efficacy, Safety, and Immunogenicity Maintained When Patients With nAMD Switch from Eylea to Biosimilar

Pavblu, a biosimilar to Eylea, also showed no clinically meaningful differences in efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).

administrator

Related Articles